Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07512050

Oral Lactobacillus Reuteri for Skin Barrier Dysfunction in Obesity

A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Oral Lactobacillus Reuteri in Treating Skin Barrier Function Impairment Caused by Obesity.

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
140 (estimated)
Sponsor
Shenzhen People's Hospital · Academic / Other
Sex
All
Age
18 Years – 40 Years
Healthy volunteers
Accepted

Summary

This clinical trial aims to evaluate the safety and efficacy of oral Lactobacillus reuteri supplementation for treating obesity-induced skin barrier impairment in individuals aged 18-40 with a BMI ≥30. The study focuses on the following questions: Can oral Lactobacillus reuteri supplementation reduce skin barrier damage (measured by transepidermal water loss/TEWL) in obese participants? Does modulation of gut microbiota with Lactobacillus reuteri impact skin barrier function and systemic inflammation? Researchers will compare outcomes across two groups: Intervention Group (Obese): Oral Lactobacillus reuteri capsules. Placebo Control Group (Obese): Oral inactive (heat-killed) Lactobacillus reuteri. Participant Procedures: Take daily oral capsules (Lactobacillus reuteri or inactive strain) for 4 weeks. Undergo non-invasive skin testing (TEWL measurements) at baseline and study completion. Provide stool and samples for analyses. Complete weekly check-ins to report adverse effects (e.g., gastrointestinal discomfort, skin irritation).

Conditions

Interventions

TypeNameDescription
BIOLOGICALOral Lactobacillus reuteri group1×10\^11 CFU of inactive Lactobacillus reuteri was given orally once daily for one month
BIOLOGICALOral administration of inactive Lactobacillus reuteri group1×10\^11 CFU of inactive Lactobacillus reuteri was given orally once daily for one month

Timeline

Start date
2026-04-10
Primary completion
2026-06-28
Completion
2026-07-30
First posted
2026-04-06
Last updated
2026-04-06

Source: ClinicalTrials.gov record NCT07512050. Inclusion in this directory is not an endorsement.